Antev

Ph3 ready hor­mone ther­a­py com­pany with an in­jectable, long-act­ing GnRH an­ta­g­on­ist for pros­tate can­cer and be­nign pro­stat­ic hy­per­pla­sia. An in­jectable en­ables ex­tend­ed drug ac­tiv­i­ty, which is im­por­tant... [more in­for­ma­tion]

Apexigen

De­vel­op­ing CD40 ag­on­ist mAb; 170+ pts dosed in sin­gle agent and com­bi sett­ings. 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. Da­ta from Ph 1b of Ph 1/2 1L panc can­cer trial (col­lab... [more in­for­ma­tion]

AsclepiX Therapeutics

Pri­vate, oph­thal­mol­o­gy fo­cused ear­ly stage com­pany; tech­nol­o­gy out of Johns Hop­kins. Plan­n­ing 4Q19 IND and 1Q20 Ph1/2 ini­ti­a­tion (DME and Wet AMD). AX­T107: nov­el pep­tide in­hibit­ing VEGF and ac­ti­vat­ing... [more in­for­ma­tion]

BlinkBio, Inc.

The Com­pany is de­vel­op­ing drug con­ju­gate ther­a­pies with im­proved ther­a­peu­tic in­dex over con­tem­po­rary ADCs. They have in­no­vat­ed a plat­form based on Tun­able Drug Con­ju­gate (TDCs) ther­a­pies used to... [more in­for­ma­tion]

Caribou Biosciences

Cari­bou Bio­s­ciences is a pi­oneer in the rev­o­lu­tio­nary field of CRIS­PR-Cas genome edit­ing. Our pro­pri­e­tary tech­nol­o­gy puts us at the fore­front of the de­vel­op­ment of new med­i­cal ther­a­pies and bio-based... [more in­for­ma­tion]

CureVac AG

Found­ing Co of mR­NA space (last round $1bn+). Na­t­u­ral­ly se­quenced, op­ti­mized mR­NA. In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1... [more in­for­ma­tion]

Elstar Therapeutics, Inc.

El­s­tar Ther­a­peu­tics is ful­filling the promise of pre­ci­sion can­cer im­munother­a­py through a pow­er­ful new ap­proach to gen­er­at­ing anti­body-based, mul­ti-func­tio­n­al ther­a­peu­tics. Armed with a unique... [more in­for­ma­tion]

FLX Bio

FLX Bio, Inc. is a pri­vate­ly-held bio­phar­ma­ceu­ti­cal com­pany fo­cused on the dis­cov­ery, de­vel­op­ment and com­mer­cial­iza­tion of nov­el im­muno-on­col­o­gy agents. The com­pany lev­er­ages its unique in­sights in... [more in­for­ma­tion]

Goldfinch Bio

Goldfinch Bio is a biotech­nol­o­gy com­pany that is sin­gu­lar­ly fo­cused on dis­cov­er­ing and de­vel­op­ing pre­ci­sion ther­a­pies for pa­tients with kid­ney dis­eas­es. Just as the goldfinch has long been a sym­bol of... [more in­for­ma­tion]

Grace Therapeutics

: self-fund­ed - 2 Ph 3 pro­grams in subarach­noid he­m­or­rhage (NDA fil­ing in 2019) and ataxia te­langiec­s­ta­sia, 1 Ph 2/3 in pos­ther­pet­ic neu­ral­gia (PHN) [all ap­proved or­phan desig­na­tion]; 2 add’l... [more in­for­ma­tion]

Intensity Therapeutics

Sub­si­diary of Por­tage Biotech (seed in­ves­tor in Bio­haven). Raised $10m Se­ries A in June 2016 (In­ves­tors: Fast­For­ward In­no­va­tions, Bat­ter­son VC, VCap­i­tal, De­clan Doo­gan, Jim Mel­lon). DfuseRx℠... [more in­for­ma­tion]

iOx Therapeutics

Sub­si­diary of Por­tage Biotech (seed in­ves­tor in Bio­haven). Launched by Lud­wig Can­cer Re­search & Uni­ver­si­ty of Ox­ford. De­vel­op­ing mul­ti­ple syn­thet­ic lipid com­pounds dis­cov­ered by re­search team led by... [more in­for­ma­tion]

NexImmune, Inc.

Pri­vate IO com­pany de­vel­op­ing unique ap­proach to anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing... [more in­for­ma­tion]

Oyster Point Pharma, Inc.

Oys­ter Point is a clin­i­cal stage phar­ma­ceu­ti­cal com­pany lev­er­ag­ing neu­ro­s­cience to dis­cov­er, de­vel­op and com­mer­cial­ize nov­el ther­a­pies to treat dis­eas­es with high un­met needs. The com­pany’s ini­tial... [more in­for­ma­tion]

Pharvaris

Phar­varis is a pre­clin­i­cal stage com­pany fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and... [more in­for­ma­tion]

PsiOxus Therapeutics

IV ad­min­is­tered T-SIGn on­co virus plat­form trans­forms ade­n­ovirus in­to “armed” vec­tor. The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune... [more in­for­ma­tion]

Quentis Therapeutics

Pre­clin­i­cal stage biotech­nol­o­gy com­pany trans­lat­ing nov­el bi­ol­o­gy in­to new ther­a­peu­tic ap­proach­es that tar­get path­ways as­so­ci­at­ed with en­do­plas­mic retic­u­lum (ER) stress re­sponse. Lead pro­gram is a... [more in­for­ma­tion]

Tango Therapeutics

Tan­go Ther­a­peu­tics is a biotech­nol­o­gy com­pany ded­i­cat­ed to dis­cov­er­ing nov­el drug tar­gets and de­liv­er­ing the next gen­er­a­tion of tar­get­ed ther­a­pies to peo­ple with can­cer. Us­ing an ap­proach that starts... [more in­for­ma­tion]

TRIGR Therapeutics

TRI­GR is de­vel­op­ing a bis­pe­cif­ic anti­body plat­form (BsAb) with 4 com­pounds in the pipe­line, one clin­i­cal stage, du­al an­gio­ge­n­e­sis in­hibi­tor (TR009) and 3 im­muno­mo­d­u­la­to­ry du­al check­point and T cell... [more in­for­ma­tion]

Viela Bio

Pi­oneer­ing and ad­vanc­ing treat­ments for se­vere in­flam­ma­tion and au­toim­mune dis­eas­es by se­lec­tive­ly tar­get­ing shared crit­i­cal path­ways driv­ing dis­ease patho­ge­n­e­sis. Lead pro­gram, Ine­bi­l­izumab, is a... [more in­for­ma­tion]